Rethinking Pharmaceutical Companies' Out-of-Hospital Patient Management in the Era of Volume-Based Procurement

China's pharmaceutical industry is undergoing significant policy changes and resource redistribution.

Since 2017, the implementation of policies such as volume-based procurement, national reimbursement drug price negotiations, the “Two-Invoice System,” pilot programs for the “One-Invoice System,” and compliance regulations has made it difficult for the domestic prescription drug market—particularly for off-patent originator drugs and generics—to sustain business models with consistently high gross margins. This has significantly exacerbated the industry’s pain points of high costs and low efficiency.

Deepening the in-hospital market and broadening the out-of-hospital market are common imperatives for pharmaceutical companies during periods of painful transition. In this context, out-of-hospital patient management has emerged as a new growth driver. Pharmaceutical companies must not only focus on developing superior drugs but also adopt a “patient-centric” approach to provide full-cycle patient management across the entire disease journey. By extending solutions throughout the entire diagnosis and treatment process and related services, they can deliver precise, efficient, convenient, and accessible healthcare services to patients.

As a significant volume of prescription drugs shifts to out-of-hospital channels, the physician-centric business model is transitioning toward a patient-centric approach. Pharmaceutical companies must adapt to this trend by prioritizing consumer-facing channels and the out-of-hospital retail market, making out-of-hospital patient management a new driver of sales growth. It has become widely acknowledged that “neglecting the out-of-hospital market will result in substantial patient attrition,” prompting the industry to actively develop digital solutions for out-of-hospital patient management.

Out-of-hospital patient services represent a rapidly growing market, projected to rival the in-hospital patient management market within three to five years. In recent years, with the entry of third-party enterprises as key implementers, out-of-hospital patient management has entered an era of proactive management, becoming more comprehensive and data-driven.

However, overall, the Chinese market for out-of-hospital patient management is still in its introductory phase, and precise, efficient, and low-cost solutions remain a scarce resource in the industry.

What are the core strategies for the accumulation and management of compliance-related data assets in pharmaceutical companies? How can patient management be conducted effectively? How are leading pharmaceutical companies exploring out-of-hospital patient management? To address these questions, VCBeat will join forces with Jingli Technology to host an online roundtable seminar titled “New Perspectives on Out-of-Hospital Patient Management for Pharmaceutical Companies in the Era of Centralized Procurement.” The event will focus on hot topics such as the current state of out-of-hospital patient management, data accumulation, and regulatory compliance, aiming to clarify the development pathway for out-of-hospital patient management.

"New Perspectives on Out-of-Hospital Patient Management for Pharmaceutical Companies in the Era of Centralized Procurement"

Tuesday, July 12, 19:30-20:30

Wu ShanExecutive Director, AstraZeneca China

Head of the Breast Cancer Business Unit, Oncology Division

Zhou Shujie, Deputy IT Director at Merck & Co.

Head of Patient Services Solutions

Wan Jiang, Director of Betta Pharmaceuticals

Senior Vice President and Chief Operating Officer

Yu Junfeng, VP of Jingli Technology

Head of Medical Business Division

Live Streaming

Founded in 2016, Jingli Technology is the service provider with the most extensive experience in the medical and consumer health sectors within the private domain ecosystem. It has pioneered the first out-of-hospital patient management solution based on the WeChat ecosystem. Leveraging a digital service system grounded in evidence-based medicine, intelligent product tools, and an excellent service and quality control framework, Jingli Technology has created GemCare, the “proactive” out-of-hospital digital health platform that best understands patients. Centered on patients, GemCare optimizes overall social medical resources and continuously improves patient health outcomes.

VCBeat, founded in 2014, is a novel industry service provider that leverages data as its foundation, research as its core, and brand media as its connector to facilitate the precise aggregation of industrial resources and accelerate the growth of industry changemakers. It offers services such as brand communication, research consulting, data monitoring, and resource/project matchmaking to enterprises, government industrial parks, investment institutions, and other stakeholders across the industry chain.

“VB Think Tank” is one of VCBeat’s flagship events, serving as a face-to-face platform centered on exploring solutions in the healthcare sector, with the mission to “focus on practical challenges and discuss industry trends.” The event conducts in-depth discussions, analyses, and exchanges around the current state of development related to core themes, addressing key difficulties, pain points, and obstacles. Meanwhile, it delves into the resource endowments of participating enterprises, fostering practical collaborations through intellectual exchange.

【Scan the QR Code to Register】(Add our assistant to join the discussion group and get early access to industry news and live stream details)

【Contact the Company】(Contact Jingli Technology for business cooperation and inquiries)